The U.S. Food and Drug Administration (FDA) has declined to approve a new drug intended to help people quit smoking. The medication, developed by Achieve Life Sciences, aimed to reduce nicotine cravings without mimicking nicotine’s effects. The FDA cited insufficient evidence demonstrating the drug’s effectiveness in helping smokers successfully abstain. Achieve Life Sciences expressed disappointment with the decision, arguing their clinical trial data supported approval and plan to seek further guidance from the agency. This rejection represents a setback for those seeking alternative smoking cessation options beyond traditional nicotine replacement therapies and prescription medications. The company’s stock price fell sharply following the announcement, reflecting investor concerns about the drug’s future. This decision underscores the rigorous standards the FDA applies to new pharmaceutical approvals.